Efficacy and Immunomodulating Properties of Eltrombopag in Aplastic Anemia Following Autologous Stem Cell Transplant: Case Report and Review of the Literature

Overview

Journal Pharmaceuticals (Basel)

Publisher MDPI

Specialty Chemistry

Date 2022 Apr 23

PMID 35455416

Authors

Marta Bortolotti

Loredana Pettine

Anna Zaninoni

Giorgio Alberto Croci

Wilma Barcellini

Bruno Fattizzo

Affiliations

Soon will be listed here.

Abstract

Thrombopoietin receptor agonists (TPO-RA) are currently indicated for the treatment of chronic immune thrombocytopenia and relapsed refractory aplastic anemia. However, the off-label use of these drugs is more and more frequent, including in the setting of aplasia secondary to chemotherapy and hemopoietic stem cell transplant (SCT). Growing evidence suggests that mechanisms of action of TPO-RA go beyond the TPO-receptor stimulation and point at the immunomodulating properties of these drugs. Here, we present a case of prolonged bone marrow aplasia secondary to autologous SCT treated with eltrombopag. We describe the clinical efficacy and the immunomodulating effect of this drug on inflammatory cytokine profile and bone marrow histology. Furthermore, we provide a review of the most recent literature highlighting the efficacy and safety of TPO-RA after SCT and chemotherapy for hematologic conditions.

Citing Articles

Thrombopoietin Receptor Agonists in Post-Hematopoietic Cell Transplantation Complicated by Prolonged Thrombocytopenia: A Comprehensive Review.

Elsayed A, Elsayed B, Elmarasi M, Elsabagh A, Elsayed E, Elmakaty I Immunotargets Ther. 2024; 13:461-486.

PMID: 39290805 PMC: 11407319. DOI: 10.2147/ITT.S463384.

Successful recovery of poor graft function by administration of romiplostim in a multiple myeloma case with poor graft function following autologous stem cell transplantation.

Yim J, Park S, Lee J, Yoon J, Kim H, Min C Blood Res. 2023; 58(4):237-240.

PMID: 38031472 PMC: 10758637. DOI: 10.5045/br.2023.2023185.

Drug Design and Development for Rare Hematologic Diseases.

Fattizzo B, Capecchi M, Motta I Pharmaceuticals (Basel). 2023; 16(10).

PMID: 37895940 PMC: 10609818. DOI: 10.3390/ph16101469.

Emerging Roles of the Iron Chelators in Inflammation.

Di Paola A, Tortora C, Argenziano M, Marrapodi M, Rossi F Int J Mol Sci. 2022; 23(14).

PMID: 35887336 PMC: 9318075. DOI: 10.3390/ijms23147977.

References

Ito M, Kanda S, Yoshida T, Okuma Y, Jo H, Fukuhara S . Eltrombopag olamine for refractory immune-related thrombocytopenia induced by pembrolizumab in a non-small cell lung cancer patient. Lung Cancer. 2020; 146:362-365. DOI: 10.1016/j.lungcan.2020.05.015. View

Suyama T, Hagihara M, Kubota N, Osamura Y, Shinka Y, Miyao N . Acquired amegakaryocytic thrombocytopenia after durvalumab administration. J Clin Exp Hematop. 2021; 61(1):53-57. PMC: 8053569. DOI: 10.3960/jslrt.20047. View

Di Paola A, Palumbo G, Tortora C, Argenziano M, Catanoso M, Di Leva C . Eltrombopag in paediatric immune thrombocytopenia: Iron metabolism modulation in mesenchymal stromal cells. Br J Haematol. 2021; 197(1):110-119. PMC: 9303225. DOI: 10.1111/bjh.18012. View

Kanameishi S, Otsuka A, Nonomura Y, Fujisawa A, Endo Y, Kabashima K . Idiopathic thrombocytopenic purpura induced by nivolumab in a metastatic melanoma patient with elevated PD-1 expression on B cells. Ann Oncol. 2015; 27(3):546-7. DOI: 10.1093/annonc/mdv580. View

Marotta S, Marano L, Ricci P, Cacace F, Frieri C, Simeone L . Eltrombopag for post-transplant cytopenias due to poor graft function. Bone Marrow Transplant. 2019; 54(8):1346-1353. DOI: 10.1038/s41409-019-0442-3. View

Di Paola A, Palumbo G, Merli P, Argenziano M, Tortora C, Strocchio L . Effects of Eltrombopag on In Vitro Macrophage Polarization in Pediatric Immune Thrombocytopenia. Int J Mol Sci. 2020; 22(1). PMC: 7796119. DOI: 10.3390/ijms22010097. View

Calmettes C, Vigouroux S, Tabrizi R, Milpied N . Romiplostim (AMG531, Nplate) for secondary failure of platelet recovery after allo-SCT. Bone Marrow Transplant. 2011; 46(12):1587-9. DOI: 10.1038/bmt.2011.179. View

Zhu Q, Yang S, Zeng W, Li M, Guan Z, Zhou L . A Real-World Observation of Eltrombopag and Recombinant Human Thrombopoietin (rhTPO) in Lymphoma Patients With Chemotherapy Induced Thrombocytopenia. Front Oncol. 2021; 11:701539. PMC: 8418194. DOI: 10.3389/fonc.2021.701539. View

Tanaka T, Inamoto Y, Yamashita T, Fuji S, Okinaka K, Kurosawa S . Eltrombopag for Treatment of Thrombocytopenia after Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2016; 22(5):919-24. DOI: 10.1016/j.bbmt.2016.01.018. View

10.

Yaman Y, Elli M, Sahin S, Ozdilli K, Bilgen H, Bayram N . Eltrombopag for treatment of thrombocytopenia after allogeneic hematopoietic cell transplantation in children: Single-centre experience. Pediatr Transplant. 2021; 25(5):e13962. DOI: 10.1111/petr.13962. View

11.

Matsumoto R, Ito K, Hosono N, Matsuda Y, Tai K, Sakamaki I . Acute myeloid leukemia developing secondary immune thrombocytopenia after umbilical cord blood transplantation. Rinsho Ketsueki. 2017; 58(5):433-437. DOI: 10.11406/rinketsu.58.433. View

12.

Peffault de Latour R, Kulasekararaj A, Iacobelli S, Terwel S, Cook R, Griffin M . Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia. N Engl J Med. 2022; 386(1):11-23. DOI: 10.1056/NEJMoa2109965. View

13.

Younan R, Raad R, Sawan B, Said R . Aplastic anemia secondary to dual cancer immunotherapies a physician nightmare: case report and literature review. Allergy Asthma Clin Immunol. 2021; 17(1):112. PMC: 8549247. DOI: 10.1186/s13223-021-00616-4. View

14.

Mahat U, Rotz S, Hanna R . Use of Thrombopoietin Receptor Agonists in Prolonged Thrombocytopenia after Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2019; 26(3):e65-e73. DOI: 10.1016/j.bbmt.2019.12.003. View

15.

Lambert M, Witmer C, Kwiatkowski J . Therapy induced iron deficiency in children treated with eltrombopag for immune thrombocytopenia. Am J Hematol. 2017; 92(6):E88-E91. DOI: 10.1002/ajh.24705. View

16.

Dickinson M, Cherif H, Fenaux P, Mittelman M, Verma A, Portella M . Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia. Blood. 2018; 132(25):2629-2638. PMC: 6337824. DOI: 10.1182/blood-2018-06-855221. View

17.

Al-Samkari H, Parnes A, Goodarzi K, Weitzman J, Connors J, Kuter D . A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies. Haematologica. 2020; 106(4):1148-1157. PMC: 8018116. DOI: 10.3324/haematol.2020.251900. View

18.

Broudy V, Lin N . AMG531 stimulates megakaryopoiesis in vitro by binding to Mpl. Cytokine. 2003; 25(2):52-60. DOI: 10.1016/j.cyto.2003.05.001. View

19.

Frey N, Jang J, Szer J, Illes A, Kim H, Ram R . Eltrombopag treatment during induction chemotherapy for acute myeloid leukaemia: a randomised, double-blind, phase 2 study. Lancet Haematol. 2019; 6(3):e122-e131. DOI: 10.1016/S2352-3026(18)30231-X. View

20.

Battipaglia G, Ruggeri A, Brissot E, Mamez A, Malard F, Belhocine R . Safety and feasibility of romiplostim treatment for patients with persistent thrombocytopenia after allogeneic stem cell transplantation. Bone Marrow Transplant. 2015; 50(12):1574-7. DOI: 10.1038/bmt.2015.182. View